Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

610

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Esophageal Squamous Cell CarcinomaEsophageal CancerOesophageal Cancer
Interventions
DRUG

Docetaxel

25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.

DRUG

Cisplatin

25mg/ m2 on days 1, 8, 15 and 22.

RADIATION

Radiation

Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).

PROCEDURE

Surgery

McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

DRUG

Vinorelbine

25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).

DRUG

Cisplatin

75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER